JP2020517727A - 安定なカンナビノイド製剤 - Google Patents

安定なカンナビノイド製剤 Download PDF

Info

Publication number
JP2020517727A
JP2020517727A JP2019558668A JP2019558668A JP2020517727A JP 2020517727 A JP2020517727 A JP 2020517727A JP 2019558668 A JP2019558668 A JP 2019558668A JP 2019558668 A JP2019558668 A JP 2019558668A JP 2020517727 A JP2020517727 A JP 2020517727A
Authority
JP
Japan
Prior art keywords
cannabidiol
formulation
patient
administering
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019558668A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517727A5 (https=
Inventor
バンガラ，キラン・クマール
リー，ホワグワン
イェン，ニンシン
グエン，ヒュン・キュー
ゴスコンダ，ベンカット・アール
Original Assignee
インシス・ディベロップメント・カンパニー・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/499,178 external-priority patent/US12544389B2/en
Application filed by インシス・ディベロップメント・カンパニー・インコーポレイテッド filed Critical インシス・ディベロップメント・カンパニー・インコーポレイテッド
Publication of JP2020517727A publication Critical patent/JP2020517727A/ja
Publication of JP2020517727A5 publication Critical patent/JP2020517727A5/ja
Priority to JP2022089421A priority Critical patent/JP2022130390A/ja
Priority to JP2024113145A priority patent/JP2024161363A/ja
Priority to JP2025077149A priority patent/JP2025118787A/ja
Priority to JP2025077148A priority patent/JP2025118786A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019558668A 2017-04-27 2017-09-22 安定なカンナビノイド製剤 Pending JP2020517727A (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2022089421A JP2022130390A (ja) 2017-04-27 2022-06-01 安定なカンナビノイド製剤
JP2024113145A JP2024161363A (ja) 2017-04-27 2024-07-16 安定なカンナビノイド製剤
JP2025077149A JP2025118787A (ja) 2017-04-27 2025-05-07 安定なカンナビノイド製剤
JP2025077148A JP2025118786A (ja) 2017-04-27 2025-05-07 安定なカンナビノイド製剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/499,178 US12544389B2 (en) 2014-05-29 2017-04-27 Stable cannabinoid formulations
US15/499,178 2017-04-27
PCT/US2017/052897 WO2018200024A1 (en) 2017-04-27 2017-09-22 Stable cannabinoid formulations

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2022089421A Division JP2022130390A (ja) 2017-04-27 2022-06-01 安定なカンナビノイド製剤
JP2024113145A Division JP2024161363A (ja) 2017-04-27 2024-07-16 安定なカンナビノイド製剤

Publications (2)

Publication Number Publication Date
JP2020517727A true JP2020517727A (ja) 2020-06-18
JP2020517727A5 JP2020517727A5 (https=) 2020-11-12

Family

ID=63920361

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2019558668A Pending JP2020517727A (ja) 2017-04-27 2017-09-22 安定なカンナビノイド製剤
JP2022089421A Pending JP2022130390A (ja) 2017-04-27 2022-06-01 安定なカンナビノイド製剤
JP2024113145A Pending JP2024161363A (ja) 2017-04-27 2024-07-16 安定なカンナビノイド製剤
JP2025077148A Pending JP2025118786A (ja) 2017-04-27 2025-05-07 安定なカンナビノイド製剤
JP2025077149A Pending JP2025118787A (ja) 2017-04-27 2025-05-07 安定なカンナビノイド製剤

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2022089421A Pending JP2022130390A (ja) 2017-04-27 2022-06-01 安定なカンナビノイド製剤
JP2024113145A Pending JP2024161363A (ja) 2017-04-27 2024-07-16 安定なカンナビノイド製剤
JP2025077148A Pending JP2025118786A (ja) 2017-04-27 2025-05-07 安定なカンナビノイド製剤
JP2025077149A Pending JP2025118787A (ja) 2017-04-27 2025-05-07 安定なカンナビノイド製剤

Country Status (4)

Country Link
EP (2) EP4516355A3 (https=)
JP (5) JP2020517727A (https=)
CA (1) CA3062814C (https=)
WO (1) WO2018200024A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022130390A (ja) * 2017-04-27 2022-09-06 フレッシュ・カット・ディベロップメント・エル・エル・シー 安定なカンナビノイド製剤
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤
JP2023546648A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 包装された製剤
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
GB2584140A (en) * 2019-05-23 2020-11-25 Gw Res Ltd Use of cannabidiol in the treatment of epileptic spasms
EP4028059B1 (en) * 2019-09-09 2025-12-24 Cardiol Therapeutics Inc. Stable medicinal cannabidiol compositions
CA3157812C (en) * 2019-10-25 2024-10-22 Cardiol Therapeutics Inc. Cannabidiol compositions for use in treating heart conditions
GB2588461A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of absence epilepsy
AU2022312764A1 (en) * 2021-07-13 2024-01-18 Epm (Ip), Inc. Cannabidiolic acid esters for treating prader-willi syndrome
EP4376820A1 (en) * 2021-07-28 2024-06-05 GW Research Limited Use of cannabidiol in the treatment of epilepsy
US20260108540A1 (en) * 2022-10-12 2026-04-23 Leiutis Pharmaceuticals Llp Novel liquid oral formulations of cannabidiol
CN116172988A (zh) * 2022-11-18 2023-05-30 中国人民解放军军事科学院军事医学研究院 大麻二酚用于制备急性放射病的药物的用途
CN115887426A (zh) * 2022-11-18 2023-04-04 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备核辐射损伤后骨髓恢复药物中的应用
CN116444351A (zh) * 2022-11-18 2023-07-18 中国人民解放军军事科学院军事医学研究院 一种核辐射损伤中对小肠有保护作用的天然小分子化合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538893A (ja) * 2006-06-01 2009-11-12 ジーダブリュー・ファーマ・リミテッド カンナビノイドの新規な使用
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008509142A (ja) * 2004-08-03 2008-03-27 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすためのブプロピオンと第２の化合物との組合せ
EP1957509A4 (en) * 2005-11-23 2010-10-27 Ironwood Pharmaceuticals Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20130210821A1 (en) * 2010-05-27 2013-08-15 James E. Vath Methods for Treating Obesity
US20160367496A1 (en) * 2014-05-29 2016-12-22 Insys Development Company, Inc. Stable cannabinoid formulations
US20160271252A1 (en) 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
CA2950424C (en) 2014-05-29 2023-03-14 Insys Pharma, Inc. Stable cannabinoid formulations
US11331279B2 (en) 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CA3062814C (en) * 2017-04-27 2023-11-14 Insys Development Company, Inc. Stable cannabinoid formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538893A (ja) * 2006-06-01 2009-11-12 ジーダブリュー・ファーマ・リミテッド カンナビノイドの新規な使用
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"History of Changes for Study: NCT02844933, Cannabidiol Oral Solution for The Treatment of Subjects W", CLINICAL TRIALS.GOV ARCHIVE [ONLINE], JPN6022029773, 31 March 2017 (2017-03-31), ISSN: 0004826038 *
PHARMACOLOGY, BIOCHEMISTRY AND BEHAVIOR, vol. 98, JPN6021023816, 2011, pages 268 - 272, ISSN: 0004826037 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
JP2022130390A (ja) * 2017-04-27 2022-09-06 フレッシュ・カット・ディベロップメント・エル・エル・シー 安定なカンナビノイド製剤
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤
JP2023546648A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 包装された製剤
JP7752171B2 (ja) 2020-09-24 2025-10-09 ニコベンチャーズ トレーディング リミテッド 包装された製剤

Also Published As

Publication number Publication date
CA3062814C (en) 2023-11-14
EP3615079C0 (en) 2025-02-12
EP3615079B1 (en) 2025-02-12
EP3615079A4 (en) 2020-09-23
JP2024161363A (ja) 2024-11-19
JP2025118786A (ja) 2025-08-13
JP2022130390A (ja) 2022-09-06
CA3062814A1 (en) 2018-11-01
EP4516355A2 (en) 2025-03-05
WO2018200024A1 (en) 2018-11-01
EP3615079A1 (en) 2020-03-04
EP4516355A3 (en) 2025-05-28
JP2025118787A (ja) 2025-08-13

Similar Documents

Publication Publication Date Title
AU2024266845B2 (en) Stable cannabinoid formulations
US20250017875A1 (en) Stable cannabinoid formulations
JP2024161363A (ja) 安定なカンナビノイド製剤
US12544389B2 (en) Stable cannabinoid formulations
US20220054450A1 (en) Stable cannabinoid formulations
US20220280446A1 (en) Stable cannabinoid formulations
US20160271252A1 (en) Stable cannabinoid formulations
US20220125932A1 (en) Stable cannabinoid formulations
CA3025702C (en) Stable cannabinoid formulations

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200923

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200923

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210419

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210629

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220601

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220601

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220620

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220621

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220715

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220726

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221003

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240410